Anemia

Anemia May Increase Risk for Kidney Failure

Publish Date August 5, 2020

Investigators found sex and racial differences in the risk for end-stage kidney disease among patients with CKD anemia.

Resistance Training May Improve Iron Deficiency in Older HD Patients

Publish Date July 23, 2020

In a study, older hemodialysis patients performing resistance exercise for 24 weeks saw their iron bioavailability increase.

Study: Targeting Higher Hemoglobin May Improve Fatigue in CKD

Publish Date July 21, 2020

For patients with chronic kidney disease (CKD) receiving erythropoiesis-stimulating agents (ESAs), achieving hemoglobin (Hb) levels higher than guideline-recommended target range is associated with a small but potentially clinically significant improvement in fatigue, although not in the ability to perform usual daily work or other activities. In a systematic review and meta-analysis of 15 randomized trials…

Maintenance IV Iron May Improve Erythropoietin Resistance in HD

Publish Date July 16, 2020

This study investigated intravenous iron in hemodialysis patients with functional iron deficiency anemia.

Limited ESA Use in COVID-19 Patients Recommended

Publish Date July 6, 2020

Infection with the virus that causes COVID-19, coupled with use of erythropoiesis-stimulating agents may result in additive prothrombotic effects, according to the authors.

Molidustat Noninferior to Darbepoetin in Nondialysis CKD

Publish Date June 19, 2020

In 2 Japanese trials of nondialysis patients, molidustat proved noninferior to darbepoetin alfa, an erythropoiesis-stimulating agent, in correcting and maintaining hemoglobin levels over 36 weeks.

Blood Donors Will Get Results of Coronavirus Antibody Test, Red Cross Says

Publish Date June 15, 2020

Positive test result does not confirm immunity to the virus, and test is not meant to diagnose illness.

Roxadustat Noninferior to Darbepoetin in Treating Renal Anemia

Publish Date June 11, 2020

In separate active comparator studies, roxadustat achieved hemoglobin correction in CKD patients and maintained hemoglobin within target range in hemodialysis patients at least as well as darbepoetin alfa over 24 weeks.

No Ophthalmic Effects From Roxadustat Short Term

Publish Date June 10, 2020

In a study of patients on dialysis, investigators found no higher risk for retinal hemorrhages and other ophthalmic problems among roxadustat-treated patients compared with patients receiving darbepoetin alfa.

Most Teens Recover Iron Stores One Year After Whole Blood Donation

Publish Date June 5, 2020

Less than half of blood donors with low ferritin at index achieved adequate stores within 12 months.